Tyrosine kinase inhibitorFDA-approvedSecond-line
Mekinist
Generic name: trametinib
How it works
Blocks the MEK protein, which is involved in the signaling pathway that can drive the growth of cancer cells. By blocking MEK, trametinib can slow or stop the growth of cancer cells.
Cancer types
Melanoma— BRAF V600E-positive
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 4 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Dabrafenib and Trametinib Before and After Surgery for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| MEK Inhibitors Show Promise in Treating Resistant Rectal Cancer | Colorectal Cancer | lab-study | — | Source → |
| Reduced-Dose Dabrafenib-Trametinib for Lung Cancer in Very Elderly Patient | Lung Cancer | observational | — | Source → |
| Treating Advanced Melanoma with Combination Therapies | Melanoma | phase-3 | — | Source → |
| Dabrafenib and Trametinib Rollover Study for Various Cancers | Lung Cancer | preclinical | — | Source → |
| New Trial Investigates Treatment for Newly Diagnosed Juvenile Myelomonocytic Leukemia | Leukemia | phase-1 | — | Source → |
| Trametinib Shows Promise as Second-Line Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 27.8%, and the disease control rate was 72.2%. | Source → |
| Study Examines Treatment Options for Lung Cancer Patients with Specific Genetic Mutation | Lung Cancer | observational | Median progression-free survival was 7.5 months and median overall survival was 18.7 months in patients treated with dabrafenib and trametinib. | Source → |
| Personalized therapy for pancreatic cancer using patient-derived organoids | Pancreatic Cancer | lab-study | The Gem/PTX regimen achieved 75 -95% growth inhibition in PDOs. | Source → |
| Comparing Treatments for Melanoma Patients | Melanoma | meta-analysis | Dabrafenib and trametinib improved recurrence-free survival (RFS) compared to anti-PD(L)1 therapies (hazard ratio [HR] 0.53, 95% CI, 0.40-0.70, P < .01). | Source → |
| Combining two cancer drugs may help overcome melanoma resistance | Melanoma | lab-study | — | Source → |
| Targeted Therapy Shows Promise in Treating Pediatric Melanoma | Melanoma | observational | — | Source → |
| Rare Eye Condition Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Trametinib Helps Young Children with Advanced Leukemia | Leukemia | phase-2 | The objective response rate was 50%. | Source → |
| Rare Lung Cancer Patient Responds to Dabrafenib and Trametinib | Lung Cancer | observational | — | Source → |
| Neoadjuvant dabrafenib and trametinib for stage III melanoma: 5-year results | Melanoma | phase-2 | At 5 years, recurrence-free survival was 40% (95% CI 27% to 60%), distant metastasis-free survival was 57% (95% CI 42% to 76%), and overall survival was 80% (95% CI 67% to 94%). | Source → |
| Rare but Life-Threatening Side Effect of Melanoma Treatment | Melanoma | observational | — | Source → |
| Combining Medications for Advanced Melanoma Shows Promise | Melanoma | phase-2 | The confirmed objective response rate was 29.2%. | Source → |
| Combining two drugs may help some colorectal cancer patients | Colorectal Cancer | preclinical | Vertical inhibition with trametinib and cetuximab induced SD or PR in 74% of analysed models. | Source → |
| Melanoma Drug Exposure Linked to Survival | Melanoma | observational | Median overall survival was significantly longer in patients with trametinib C ≥ 15.6 ng/mL (22.8 vs. 12.6 months, P = 0.003) | Source → |
| Melanoma Treatment Comparison Study | Melanoma | phase-3 | The 2-year overall survival for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1), and arm B 51.5% (95% CI, 41.7 to 60.4). | Source → |
| Combining Two Drugs May Help Fight Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Researchers Identify New Combination Therapy for Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| New Combination Therapies Identified for Rare Leukemia | Leukemia | lab-study | — | Source → |
| Combining Celecoxib and Trametinib May Help Treat Melanoma | Melanoma | lab-study | — | Source → |
| Rare Cancer Responds to Combination Therapy | Ovarian Cancer | lab-study | — | Source → |
| Combining Metformin with Trametinib and Paclitaxel in Melanoma Treatment | Melanoma | lab-study | — | Source → |
| Dabrafenib and Trametinib Combination Shows Promise in Lung Cancer Patients | Lung Cancer | observational | The median progression-free survival was 17.5 months and the median overall survival was 25.5 months. | Source → |
| Pembrolizumab and other drugs improve cancer outcomes in melanoma patients | Melanoma | phase-2 | Median progression-free survival was 16.9 months with the combination of pembrolizumab, dabrafenib, and trametinib, compared to 10.7 months with dabrafenib and trametinib alone. | Source → |
| Moxibustion May Enhance Effectiveness of Cancer Treatment | Breast Cancer | animal-study | The tumor inhibition rate was 50.67% in the combination group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.